Valuation: Bolt Biotherapeutics, Inc.

Market Cap 8.49M 7.42M 6.85M 6.31M 11.9M 818M 12.16M 81.86M 32.2M 401M 31.9M 31.2M 1.38B P/E 2026 *
-0.02x
P/E 2027 * -0.02x
Enterprise Value 8.49M 7.42M 6.85M 6.31M 11.9M 818M 12.16M 81.86M 32.2M 401M 31.9M 31.2M 1.38B EV / Sales 2026 *
5.63x
EV / Sales 2027 * 2.43x
Free-Float
96.53%
Yield 2026 *
-
Yield 2027 * -
1 day+5.49%
1 week+16.93%
Current month+14.81%
1 month+10.78%
3 months-6.55%
6 months-30.50%
Current year-19.17%
1 week 3.78
Extreme 3.78
4.42
1 month 3.75
Extreme 3.75
4.42
Current year 3.75
Extreme 3.75
7.2
1 year 3.75
Extreme 3.75
7.2
3 years 3.75
Extreme 3.75
31.2
5 years 3.75
Extreme 3.75
385.7
10 years 3.75
Extreme 3.75
861.4
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer - 15/05/2024
Chief Executive Officer 55 15/05/2024
Chief Operating Officer 61 15/05/2024
Director TitleAgeSince
Director/Board Member 64 01/12/2020
Director/Board Member 73 14/12/2021
Chairman 56 04/09/2024
Date Insider Type Main position Quantity % Market Cap.
10/06/26 Free

Director

5,000 0.2602%
10/06/26 Free

Director

5,000 0.2602%
10/06/26 Free

Director

5,000 0.2602%
Change 5-day change 1-year change 3-year change Capi.($)
+5.49%+16.93%-20.07%-84.55% 8.49M
+0.24%-1.54%+52.85%+60.31% 53.83B
-7.17%-4.39%+42.72%+73.70% 52.1B
+0.80%-6.31%+5.62%+413.12% 23.48B
-0.09%-0.01%-16.85%-16.17% 23.13B
+2.43%+1.29%+35.00%-6.55% 19.36B
-1.14%+0.03%+31.67%-31.21% 17.56B
-5.16%-7.00%+168.44%+291.24% 15.2B
+6.19%+1.19%+35.06%+652.77% 14.83B
+0.43%-1.03%+25.75%+186.18% 14.06B
Average +0.05%-0.67%+36.02%+153.88% 23.36B
Weighted average by Cap. -1.38%-2.35%+40.63%+138.98%

Financials

2026 *2027 *
Net sales 1.51M 1.32M 1.22M 1.12M 2.11M 145M 2.16M 14.54M 5.72M 71.16M 5.67M 5.54M 245M 3.5M 3.06M 2.82M 2.6M 4.9M 337M 5.01M 33.74M 13.27M 165M 13.14M 12.86M 568M
Net income -44.52M -38.91M -35.9M -33.09M -62.37M -4.29B -63.76M -429M -169M -2.1B -167M -164M -7.23B -47.5M -41.51M -38.3M -35.31M -66.55M -4.57B -68.02M -458M -180M -2.24B -178M -174M -7.71B
Net Debt - -
Logo Bolt Biotherapeutics, Inc.
Bolt Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company developing immunotherapies for the treatment of cancer. The Company’s pipeline includes BDC-3042, an agonist antibody that activates macrophages by targeting dectin-2, and BDC-4182, a next generation Boltbody Immune-Stimulating Antibody Conjugate (ISAC) clinical candidate targeting claudin 18.2. BDC-3042 is in a Phase I dose escalation trial that includes patients with any of seven different solid tumor types. The Company’s Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. It has two additional ISAC programs utilizing its Boltbody ISAC technology platform in preclinical development. One is a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5 (CEA). Its final Boltbody ISAC program targets PD-L1. The Company is also developing additional Boltbody ISACs in strategic collaborations with biopharmaceutical companies.
Employees
23
Date Price Change Volume
17/07/26 $4.420 +5.49% 15,969
16/07/26 $4.190 -0.48% 12,489
15/07/26 $4.210 +3.95% 21,894
14/07/26 $4.050 +7.14% 30,735
13/07/26 $3.780 0.00% 9,215
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
4.420USD
Average target price
41.00USD
Spread / Average Target
+827.60%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. BOLT Stock